We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.

Dr. Juthani Awarded the American Brain Tumor Association Young Investigator Award

You are here

Dr. Rupa Juthani with Dr. Heather Calderone, Director of Research and Grants at the American Brain Tumor Association

Dr. Rupa Gopalan Juthani was awarded the American Brain Tumor Association Young Investigator Award at the 2019 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in San Diego, California, on April 13-17.

Dr. Juthani’s abstract, “Targeted Ultra-Small Nanoparticles as a Multi-Modal Platform for Enhanced Drug Delivery to Primary and Metastatic Brain Tumors” won her the coveted prize. Her abstract tackles the difficulties of treating malignant brain tumors due to issues with drug penetration and diffusion in the central nervous system (CNS). It investigates the use of radiolabeled fluorescent ultra-small silica nanoparticles (C’dots) as a vehicle for enhanced drug delivery to the CNS, and explores the possibility of using it as a simultaneous diagnostic and therapeutic tool.

During the preclinical testing phase, Dr. Juthani studied the distribution of C’dots attached to small molecule inhibitor drugs in malignant glioma brain-tumor bearing mice and in a mouse model of non-small cell lung cancer. Dr. Juthani’s research showed that accumulation, diffusion and retention of the nanoparticle drug conjugate was significantly increased in comparison to the control group, with marked reduction in total drug dose compared to free drug in flank tumor bearing mice. Her team’s findings showed that C’dots presented a viable and attractive platform for delivering drugs through the central nervous system. This work was performed in the laboratory of Dr. Michelle Bradbury and with Dr. Cameron Brennan at Memorial Sloan Kettering, and is complemented by a concurrent non-therapeutic clinical trial.

More than 1,700 abstracts were submitted to the AANS this year. Award winners were noted to have gone above and beyond the requirements and were selected for their distinguished contributions in their field of study.

More about Dr. Juthani